Population-Based Mechanistic Prediction of Oral Drug Absorption
暂无分享,去创建一个
Sebastian Polak | Masoud Jamei | Amin Rostami-Hodjegan | Geoffrey Tucker | Sibylle Neuhoff | M. Jamei | S. Polak | G. Tucker | A. Rostami-Hodjegan | S. Neuhoff | David Turner | Jiansong Yang | D. Turner | Jiansong Yang
[1] Masoud Jamei,et al. Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.
[2] D. Thakker,et al. Rhodamine 123 Requires Carrier-Mediated Influx for Its Activity as a P-Glycoprotein Substrate in Caco-2 Cells , 2003, Pharmaceutical Research.
[3] A. Serajuddin,et al. Measurement of surface pH of pharmaceutical solids: a critical evaluation of indicator dye-sorption method and its comparison with slurry pH method. , 2008, Journal of pharmaceutical sciences.
[4] Lawrence X. Yu,et al. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .
[5] J. Kolars,et al. First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.
[6] K. Svanes,et al. Microsphere method in measurement of blood flow to wall layers of small intestine. , 1986, The American journal of physiology.
[7] P. Watkins,et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.
[8] J. Dressman,et al. Solubilization and Wetting Effects of Bile Salts on the Dissolution of Steroids , 1991, Pharmaceutical Research.
[9] L. Di,et al. Development and Application of an Automated Solution Stability Assay for Drug Discovery , 2006, Journal of biomolecular screening.
[10] E. Townley,et al. Parameters affecting absorption of griseofulvin in a human subject using urinary metabolite excretion data. , 1970, Journal of pharmaceutical sciences.
[11] J. Comer,et al. Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class. , 2008, Current drug metabolism.
[12] J. Dressman,et al. Estimation of the Increase in Solubility of Drugs as a Function of Bile Salt Concentration , 2004, Pharmaceutical Research.
[13] Geert Verreck,et al. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. , 2007, International journal of pharmaceutics.
[14] W. S. Snyder,et al. Report of the task group on reference man , 1979, Annals of the ICRP.
[15] W H Streng. The Gibbs constant and pH solubility profiles. , 1999, International journal of pharmaceutics.
[16] A. Ridolfo,et al. Benoxaprofen, a new anti-inflammatory agent: particle-size effect on dissolution rate and oral absorption in humans. , 1979, Journal of pharmaceutical sciences.
[17] L. A. Christensen,et al. pH‐Profile and regional transit times of the normal gut measured by a radiotelemetry device , 1989, Alimentary pharmacology & therapeutics.
[18] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[19] N. Eddington,et al. The influence of first pass metabolism on the development and validation of an IVIVC for metoprolol extended release tablets. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[20] E. Straus,et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.
[21] L. Knutson,et al. A new technique for segmental jejunal perfusion in man. , 1989, The American journal of gastroenterology.
[22] D. D. Bois,et al. CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .
[23] B. Gazzard,et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea , 1999, Gut.
[24] Lawrence X. Yu,et al. Predicting Oral Drug Absorption in Humans , 1999 .
[25] A. Galetin,et al. Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.
[26] Thomas J. Vidmar,et al. Predicting Drug Absorption: How Nature Made It a Difficult Problem , 2002, Journal of Pharmacology and Experimental Therapeutics.
[27] Lawrence X. Yu,et al. Characterization of small intestinal transit time distribution in humans , 1998 .
[28] G L Amidon,et al. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.
[29] R. Arnold. Diagnosis and differential diagnosis of hypergastrinemia , 2007, Wiener klinische Wochenschrift.
[30] Amin Rostami-Hodjegan,et al. The effects of portal shunts on intestinal cytochrome P450 3A activity , 2002, Hepatology.
[31] K. Pang,et al. Disparity in Intestine Disposition between Formed and Preformed Metabolites and Implications: A Theoretical Study , 2009, Drug Metabolism and Disposition.
[32] J. Comer,et al. Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution--a validation study. , 2006, Journal of pharmaceutical sciences.
[33] R. Minchin,et al. Presystemic elimination of drugs: theoretical considerations for quantifying the relative contribution of gut and liver. , 1982, Journal of pharmaceutical sciences.
[34] R. J. Hintz,et al. The effect of particle size distribution on dissolution rate and oral absorption , 1989 .
[35] N. Hosten,et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging , 2005, Alimentary pharmacology & therapeutics.
[36] P. Harriott. Mass transfer to particles: Part I. Suspended in agitated tanks , 1962 .
[37] Matthew D. Troutman,et al. Novel Experimental Parameters to Quantify the Modulation of Absorptive and Secretory Transport of Compounds by P-Glycoprotein in Cell Culture Models of Intestinal Epithelium , 2003, Pharmaceutical Research.
[38] Lawrence X. Yu. An Integrated Model for Determining Causes of Poor Oral Drug Absorption , 1999, Pharmaceutical Research.
[39] D. Dunbar,et al. Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[40] R. Remmel,et al. First-pass disposition of (-)-6-aminocarbovir in rats: II. Inhibition of intestinal first-pass metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[41] Elizabeth M. Topp,et al. Transport processes in pharmaceutical systems , 1999 .
[42] P. Pentikäinen,et al. Effect of particle size on the bioavailability of digoxin , 1975, European Journal of Clinical Pharmacology.
[43] H. Lennernäs,et al. Regional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man , 1995, Pharmaceutical Research.
[44] R. Yeates,et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole , 2004, European Journal of Clinical Pharmacology.
[45] T. Mano,et al. Solubility and dissolution profile assessment in drug discovery. , 2007, Drug metabolism and pharmacokinetics.
[46] D. Greenblatt,et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.
[47] A. Glomme,et al. Predicting the Intestinal Solubility of Poorly Soluble Drugs , 2007 .
[48] Gordon L. Amidon,et al. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.
[49] G L Amidon,et al. A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.
[50] D. Shen,et al. First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.
[51] J. Gorski,et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin , 1998, Clinical pharmacology and therapeutics.
[52] Gerd Folkers,et al. Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies , 2006 .
[53] M. Jamei,et al. Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (Simcyp V8) , 2008 .
[54] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[55] N. Chalasani,et al. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts , 2001, Hepatology.
[56] Emma L. McConnell,et al. Meal-Induced Acceleration of Tablet Transit Through the Human Small Intestine , 2009, Pharmaceutical Research.
[57] Abdul W Basit,et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. , 2008, International journal of pharmaceutics.
[58] S. Badawy,et al. Microenvironmental pH modulation in solid dosage forms. , 2007, Journal of pharmaceutical sciences.
[59] Hassan Almoazen,et al. Investigation of Solubility and Dissolution of a Free Base and Two Different Salt Forms as a Function of pH , 2005, Pharmaceutical Research.
[60] S. Davis,et al. Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .
[61] J. Herron,et al. Rapid throughput screening of apparent KSP values for weakly basic drugs using 96-well format. , 2008, Journal of pharmaceutical sciences.
[62] Alex Avdeef,et al. Absorption and Drug Development: Solubility, Permeability, and Charge State , 2003 .
[63] R. Wolen,et al. The effect of crystal size on the bioavailability of benoxaprofen: studies utilizing deuterium labeled drug. , 1979, Biomedical mass spectrometry.
[64] G. Amidon,et al. A Residence‐Time Distribution Analysis of the Hydrodynamics within the Intestine in Man during a Regional Single‐pass Perfusion with Loc‐I‐Gut: In‐vivo Permeability Estimation , 1997, The Journal of pharmacy and pharmacology.
[65] Erich Brunner,et al. Reaktionsgeschwindigkeit in heterogenen Systemen , 1904 .
[66] Mark Feldman,et al. Fasting gastric pH and its relationship to true hypochlorhydria in humans , 1991, Digestive Diseases and Sciences.
[67] J. Dressman,et al. Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update , 2008, Pharmaceutical Research.
[68] J. Dressman,et al. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine , 2004, The Journal of pharmacy and pharmacology.
[69] A. Avdeef. Solubility of sparingly-soluble ionizable drugs. , 2007, Advanced drug delivery reviews.
[70] A. Noyes,et al. The rate of solution of solid substances in their own solutions , 1897 .
[71] C. Olsson,et al. The control of gut motility. , 2001, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.
[72] M. Kansy,et al. Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[73] J. Dressman,et al. Estimating drug solubility in the gastrointestinal tract. , 2007, Advanced drug delivery reviews.
[74] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[75] Hans Lennernäs,et al. The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids , 2005, Pharmaceutical Research.
[76] A. Basit,et al. Gut instincts: explorations in intestinal physiology and drug delivery. , 2008, International journal of pharmaceutics.
[77] L. Benet,et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole , 1997, Clinical pharmacology and therapeutics.
[78] Kairui Feng,et al. The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.
[79] Stephen D. Clark,et al. Introductory Statistics—A Modelling Approach , 1995 .
[80] Lutz Trahms,et al. Magnetic Marker Monitoring: An application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. , 2005, Advanced drug delivery reviews.
[81] A. Brogna,et al. Influence of aging on gastrointestinal transit time. An ultrasonographic and radiologic study. , 1999, Investigative radiology.
[82] M. Jamei,et al. A Novel Physiologically-Based Mechanistic ModelPredicting Oral Drug Absorption: The Advanced Dissolution, Absorption, and Metabolism (ADAM) Model , 2007 .
[83] D. L. Madsen,et al. Effects of gender, age, and body mass index on gastrointestinal transit times , 1992, Digestive Diseases and Sciences.
[84] W. Nernst,et al. Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen , 1904 .
[85] J. Dressman,et al. Upper Gastrointestinal pH in Seventy-Nine Healthy, Elderly, North American Men and Women , 1993, Pharmaceutical Research.
[86] H. Paul,et al. Laboratory studies with nitrofurantoin. Relationship between crystal size, urinary excretion in the rat and man, and emesis in dogs. , 1967, Journal of pharmaceutical sciences.
[87] Abu T M Serajuddin,et al. Salt formation to improve drug solubility. , 2007, Advanced drug delivery reviews.
[88] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[89] S. Shi,et al. Proton pump inhibitors: an update of their clinical use and pharmacokinetics , 2008, European Journal of Clinical Pharmacology.
[90] Hans Lennernäs,et al. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. , 2009, Molecular pharmaceutics.
[91] S. Chong,et al. P-gp Inhibition Potential in Cell-Based Models: Which “Calculation” Method is the Most Accurate? , 2008, The AAPS Journal.
[92] J. Lin,et al. Pharmacokinetic and Pharmacodynamic Properties of Histamine H2-Receptor Antagonists , 1991, Clinical pharmacokinetics.
[93] J. Graff,et al. Gastrointestinal mean transit times in young and middle-aged healthy subjects. , 2001, Clinical physiology.
[94] L. Benet,et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction , 1992, Clinical pharmacology and therapeutics.
[95] G L Amidon,et al. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[96] M. Paine,et al. P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine , 2003, Pharmaceutical Research.
[97] R. Minchin,et al. Metabolism of drugs and other xenobiotics in the gut lumen and wall. , 1990, Pharmacology & therapeutics.
[98] N. Kaniwa,et al. Assessment of gastric acidity of Japanese subjects over the last 15 years. , 2001, Biological & pharmaceutical bulletin.
[99] C. Beglinger,et al. Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation , 1996, British journal of pharmacology.
[100] G. Amidon,et al. Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed. , 2008, Journal of pharmaceutical sciences.
[101] Kiyohiko Sugano,et al. Theoretical dissolution model of poly-disperse drug particles in biorelevant media. , 2008, Journal of pharmaceutical sciences.
[102] L Zhang,et al. A regulatory viewpoint on transporter-based drug interactions. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[103] M. Manns,et al. UDP-glucuronosyltransferase activity in human liver and colon. , 1999, Gastroenterology.
[104] M. Jamei,et al. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.
[105] M. Fromm,et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin , 1996, Hepatology.
[106] D. Flanagan,et al. General solution for diffusion-controlled dissolution of spherical particles. 2. Evaluation of experimental data. , 2002, Journal of pharmaceutical sciences.
[107] P. Cohen,et al. Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.
[108] G. Tucker,et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[109] A. Basit,et al. Interplay Between Intestinal pH, Transit Time and Feed Status on the In Vivo Performance of pH Responsive Ileo-Colonic Release Systems , 2008, Pharmaceutical Research.
[110] J. Crison,et al. Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine. , 1996, Journal of pharmaceutical sciences.
[111] Kevin C. Johnson,et al. Dissolution and Absorption Modeling: Model Expansion to Simulate the Effects of Precipitation, Water Absorption, Longitudinally Changing Intestinal Permeability, and Controlled Release on Drug Absorption , 2003, Drug development and industrial pharmacy.
[112] J. Lin,et al. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. , 1997, Biochemical pharmacology.
[113] M Rowland,et al. Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.
[114] J. Dressman,et al. Upper Gastrointestinal (GI) pH in Young, Healthy Men and Women , 1990, Pharmaceutical Research.
[115] In vivo assessment of intestinal drug metabolism. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[116] I. Gardner,et al. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[117] Amin Rostami-Hodjegan,et al. Cytochrome P450 3A expression and activity in the human small intestine , 2004, Clinical pharmacology and therapeutics.
[118] M. Fromm,et al. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique , 2001, Clinical pharmacology and therapeutics.
[119] M. J. Story,et al. Reduced bioavailability of atenolol in man : the role of bile acids , 1993 .
[120] R. Tukey,et al. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.
[121] J. DeSesso,et al. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[122] Oliver Burk,et al. Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.
[123] J. Valentin. Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.
[124] J. Hardcastle,et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. , 1988, Gut.
[125] M. Wilson,et al. Regulation of intestinal blood flow. , 2000, The Journal of surgical research.
[126] P. Hellström,et al. Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial , 2000, European Journal of Nuclear Medicine.
[127] D. D. Bois,et al. A height-weight formula to estimate the surface area of man , 1916 .
[128] D. Flanagan,et al. General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. , 1999, Journal of pharmaceutical sciences.
[129] J. Dressman,et al. Comparison of Canine and Human Gastrointestinal Physiology , 1986, Pharmaceutical Research.
[130] Mary F Paine,et al. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.
[131] M. Manns,et al. Polymorphic Gene Regulation and Interindividual Variation of UDP-glucuronosyltransferase Activity in Human Small Intestine* , 2000, The Journal of Biological Chemistry.
[132] H Lennernäs,et al. Intestinal permeability and its relevance for absorption and elimination , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[133] Amin Rostami-Hodjegan,et al. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.
[134] J. Kolars,et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.